STOCK TITAN

Perceptive Discloses 9.99% Stake in Palisade Bio (12.24M Shares)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Perceptive Advisors LLC, its founder Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. reported beneficial ownership of 12,243,018 shares of Palisade Bio, Inc. common stock, representing 9.99% of the class on a fully considered basis. The calculation uses 96,645,431 reported outstanding shares plus 25,714,285 shares from the underwriters' over-allotment and assumes exercise of Pre-Funded Warrants for 193,018 shares permitted under a stated Beneficial Ownership Limitation. The Master Fund directly holds 12,050,000 shares and 5,185,714 Pre-Funded Warrants, and Perceptive Advisors acts as investment manager; Mr. Edelman is the managing member. The filing states the position was not acquired to influence control.

Positive

  • Material stake disclosed: Combined ownership of 12,243,018 shares representing 9.99%
  • Regulatory compliance: Timely Schedule 13G filing with clear breakdown of direct holdings and warrants
  • Structured warrant limit: Beneficial Ownership Limitation prevents accidental ownership above 9.99%

Negative

  • Near-threshold concentration: Position sits immediately below the 10% level, which could limit future automatic exercises
  • Shared voting/dispositive power only: Reported sole voting and dispositive power are 0, indicating decisions are not claimed as sole control

Insights

Large passive stake disclosed just below the 10% regulatory threshold.

The filing shows a coordinated reporting group holding 12,243,018 shares, equal to 9.99%, which is material for investors because it signals a significant concentrated position without crossing the 10% reporting/beneficial ownership trigger. The position combines direct shares and Pre-Funded Warrants limited by a Beneficial Ownership Limitation that caps exercisable warrants at 193,018 shares.

This structure means further automatic exercise into additional shares is constrained unless circumstances change; monitor any changes to the Beneficial Ownership Limitation or subsequent filings for increases in ownership or changes in voting/dispositive power within the next few reporting cycles, including any amendments or Schedule 13D filings if intentions shift.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:10/09/2025
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:10/09/2025
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:10/09/2025

FAQ

What stake did Perceptive report in Palisade Bio (PALI)?

Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund reported beneficial ownership of 12,243,018 shares, equal to 9.99%.

How is the 9.99% ownership percentage calculated?

The percentage is based on 96,645,431 outstanding shares reported by the issuer plus 25,714,285 over-allotment shares and assumes exercise of Pre-Funded Warrants for 193,018 shares permitted under the Beneficial Ownership Limitation.

Does the filing indicate control of Palisade Bio?

No; the certifying statement says the securities were not acquired to change or influence control, and each Reporting Person reports 0 sole voting power and 0 sole dispositive power.

What are the Pre-Funded Warrants disclosed?

The Master Fund directly holds 5,185,714 Pre-Funded Warrants exercisable for common stock at $0.0001 per share, subject to the Beneficial Ownership Limitation which currently permits exercise for up to 193,018 shares.

Who signs the Schedule 13G for these filings?

The Schedule is signed by Joseph Edelman as Managing Member of Perceptive Advisors and on behalf of the Master Fund, dated 10/09/2025.
Palisade Bio Inc

NASDAQ:PALI

PALI Rankings

PALI Latest News

PALI Latest SEC Filings

PALI Stock Data

328.25M
136.93M
0.24%
5.92%
3.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CARLSBAD